Monday, November 2, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025E and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% during 2026-2033

    80% confidence

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence

  • Surgical Procedures dominated with 38.45% in 2025 due to their proven effectiveness, widespread availability, and established clinical use

    80% confidence

  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence

  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Surgical Procedures dominated with 38.45% in 2025 due to their proven effectiveness, widespread availability, and established clinical use

    80% confidence

  • Hospitals & Clinics dominated with 47.49% in 2025 due to their advanced infrastructure and specialized care

    80% confidence

  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence

  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence

  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence

  • Uterine fibroids are common among women between the ages of 30 to 40 years

    80% confidence

  • Uterine fibroids are common among women between the ages of 30 to 40 years, with varying rates among different ethnic groups

    80% confidence

  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence

  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence

  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence

  • MRI-Guided Focused Ultrasound expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Submucosal Fibroids dominated with 36.24% in 2025 due to their high prevalence and significant symptom severity

    80% confidence

  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25%

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence

  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,533 source documents archived
Query this data → isubstrate.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider — Source | Via News | Via News